Robotic radiosurgery in pancreatic cancer: A systematic review

被引:12
作者
Buwenge, Milly [1 ]
Cellini, Francesco [2 ]
Silvestris, Nicola [3 ]
Cilla, Savino [4 ,5 ]
Deodato, Francesco [1 ]
Macchia, Gabriella [1 ]
Mattiucci, Gian C. [6 ]
Valentini, Vincenzo [6 ]
Morganti, Alessio G. [7 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Radiat Oncol, I-86100 Campobasso, Italy
[2] Policlin Univ Campus Biomed, Dept Radiat Oncol, I-00144 Rome, Italy
[3] Natl Canc Res Ctr Giovanni Paolo II, Med Oncol Unit, I-70124 Bari, Italy
[4] Univ Cattolica Sacro Cuore, Dept Med Phys, I-86100 Campobasso, Italy
[5] Fdn Ric & Cura, I-86100 Campobasso, Italy
[6] Univ Cattolica Sacro Cuore, Dept Radiat Oncol, I-00168 Rome, Italy
[7] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med DIMES, Radiat Oncol Unit, I-40138 Bologna, Italy
关键词
Robotic; Radiosurgery; Pancreatic neoplasms; Systematic review; Review; Stereotactic radiotherapy; Pancreas; STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; CURATIVE RESECTION; COMBINED CHEMORADIOTHERAPY; PHASE-II; GEMCITABINE; ADENOCARCINOMA; SURVIVAL; CARCINOMA; OUTCOMES;
D O I
10.3748/wjg.v21.i31.9420
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: to present a systematic review of techniques and clinical results. METHODS: A systematic review of published literature was performed. Only studies reporting patient outcome after radiosurgery (single fraction) delivered with robotic devices [i.e., robotic radiosurgery (RRS)] have been analyzed. RESULTS: A total of 96 patients from 5 studies were included. The studies are characterized by small series and different methods in terms of dose, target definition, combination with chemotherapy and/or standard fractionated radiotherapy and evaluation modalities. Preliminary results are positive in terms of tumor response (ORR = 56%) and local control of the tumor (crude rate of local progressions: 19.5%). Results for median overall survival (11.4 mo) seem comparable with the ones of prolonged chemoradiation (range: 8.6-13.0 mo). However, gastrointestinal toxicity seems to be the main limitation of RRS, especially at the duodenal level. CONCLUSION: RRS allows for local treatment in a shortened time (1 fraction) compared to traditional treatments (about 1 mo), providing the possibility for an easy integration with systemic therapies. Preliminary results did not show any outcome differences compared to standard chemoradiation. Thus, further efforts to reduce gastrointestinal toxicity are strongly needed.
引用
收藏
页码:9420 / 9429
页数:10
相关论文
共 54 条
[1]   Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy [J].
Adhoute, X ;
Smith, D ;
Vendrely, Y ;
Rault, A ;
Cunha, AS ;
Legoux, JL ;
Belleannée, G ;
De Lédinghen, V ;
Couzigou, P ;
Masson, B .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2006, 30 (02) :224-230
[2]  
[Anonymous], 1979, Ann Surg, V189, P205
[3]  
[Anonymous], 2008, J CLIN ONCOL S
[4]   Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer [J].
Aristu, J ;
Cañón, R ;
Pardo, F ;
Martínez-Monge, R ;
Martin-Algarra, S ;
Ordoñez, JM ;
Villafranca, E ;
Moreno, M ;
Cambeiro, M ;
Azinovic, I .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (01) :30-36
[5]   A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer [J].
Ben-Josef, Edgar ;
Schipper, Mathew ;
Francis, Isaac R. ;
Hadley, Scott ;
Ten-Haken, Randall ;
Lawrence, Theodore ;
Normolle, Daniel ;
Simeone, Diane M. ;
Sonnenday, Christopher ;
Abrams, Ross ;
Leslie, William ;
Khan, Gazala ;
Zalupski, Mark M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05) :1166-1171
[6]   Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer [J].
Boone, Brian A. ;
Steve, Jennifer ;
Krasinskas, Alyssa M. ;
Zureikat, Amer H. ;
Lembersky, Barry C. ;
Gibson, Michael K. ;
Stoller, Ronald G. ;
Zeh, Herbert J. ;
Bahary, Nathan .
JOURNAL OF SURGICAL ONCOLOGY, 2013, 108 (04) :236-241
[7]   Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.: Definitive results of the 2000-01 FFCD/SFRO study [J].
Chauffert, B. ;
Mornex, F. ;
Bonnetain, F. ;
Rougier, P. ;
Mariette, C. ;
Bouche, O. ;
Bosset, J. F. ;
Aparicio, T. ;
Mineur, L. ;
Azzedine, A. ;
Hammel, P. ;
Butel, J. ;
Stremsdoerfer, N. ;
Maingon, P. ;
Bedenne, L. .
ANNALS OF ONCOLOGY, 2008, 19 (09) :1592-1599
[8]   Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated [J].
Chuong, Michael D. ;
Springett, Gregory M. ;
Freilich, Jessica M. ;
Park, Catherine K. ;
Weber, Jill M. ;
Mellon, Eric A. ;
Hodul, Pamela J. ;
Malafa, Mokenge P. ;
Meredith, Kenneth L. ;
Hoffe, Sarah E. ;
Shridhar, Ravi .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (03) :516-522
[9]   Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors [J].
Cleary, SP ;
Gryfe, R ;
Guindi, M ;
Greig, P ;
Smith, L ;
Mackenzie, R ;
Strasberg, S ;
Hanna, S ;
Taylor, B ;
Langer, B ;
Gallinger, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) :722-731
[10]   Long-term survival after curative resection for pancreatic ductal adenocarcinoma - Clinicopathologic analysis of 5-year survivors [J].
Conlon, KC ;
Klimstra, DS ;
Brennan, MF .
ANNALS OF SURGERY, 1996, 223 (03) :273-279